XML 42 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration Agreements and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue $ 38,429 $ 24,401
License Revenue [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 0 0
Development Revenue [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 14,587 19,446
Astellas Agreement [Member] | License Revenue [Member] | Japan [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 0 0
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 0 0
Astellas Agreement [Member] | Development Revenue [Member] | Japan [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 80 163
Astellas Agreement [Member] | Development Revenue [Member] | Europe [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 3,531 4,574
AstraZeneca Agreements [Member] | China [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 0 153
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 0 0
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue $ 10,976 $ 14,556